DrugsNews.net

Drugs Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Tafinlar"

The European Medicines Agency’s Committee for Medicinal Products for Human Use ( CHMP ) has recommended marketing authorisation for Tafinlar ( Dabrafenib ) for the treatment of adult patients with adv ...


The European Commission has granted marketing authorisation for Tafinlar ( Dabrafenib ) as an oral targeted treatment indicated in monotherapy for unresectable melanoma or metastatic melanoma in adult ...


The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ...


The FDA ( Food and Drug Administration ) has approved Mekinist ( Trametinib ) in combination with Tafinlar ( Dabrafenib ) to treat patients with advanced melanoma that is unresectable or metastatic.In ...


The FDA ( Food and Drug Administration ) granted Priority Review in metastatic melanoma for the supplemental New Drug Application ( sNDA ) for the combination of Tafinlar ( Dabrafenib ) and Mekinist ( ...


The U.S. Food and Drug Administration ( FDA ) has approved Tafinlar ( Dabrafenib ) and ( Trametinib ), administered together, for the treatment of anaplastic thyroid cancer ( ATC ) that cannot be remo ...


The European Commission has approved Tafinlar ( Dabrafenib ) in combination with Mekinist ( Trametinib ) for the adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma afte ...